Platelet-rich plasma (PRP) · Lesson 8 of 25 · 3 min

PRP vs stem cells, exosomes, hyaluronic acid and corticosteroids

How PRP compares with stem cell therapies, exosomes, hyaluronic acid and corticosteroids in mechanism, complexity, evidence and regulatory status.

Gloved hands placing a sample tube into a centrifuge

Key takeaways.

  • No single biologic emerges as universally superior in the comparative research.
  • Head-to-head comparisons between biologics are still relatively limited.
  • Stem cell approaches involve more complex preparation and greater regulatory oversight than PRP.
  • Platelets release exosomes, so part of PRP's proposed action may involve them.
  • Reviews in knee osteoarthritis have reported better pain and function scores with PRP than hyaluronic acid.
  • Exosome and stem cell therapies are not FDA-approved for therapeutic use; PRP use is off-label.

Stem cell therapies

Mesenchymal stem cells (MSCs) are the type most often used in regenerative medicine research. They are taken from sources such as bone marrow and adipose tissue, and each source has distinct characteristics. Harvesting is more invasive than a blood draw.

Some meta-analyses have ranked biologics for knee osteoarthritis, and some studies have reported better outcomes with expanded adipose-derived MSCs than with PRP. The course material advises caution with these rankings because the studies are heterogeneous. Stem cell approaches also involve more complex preparation and greater regulatory oversight.

Exosomes

Exosomes are small extracellular vesicles, 40 to 100 nanometers across, that carry proteins, lipids and microRNAs between cells. Activated platelets release them, so part of PRP's proposed action may occur through platelet-derived exosomes.

Exosome products studied as therapies often come from cultured stem cells and need complex isolation. PRP is prepared directly from the patient's blood. The course material notes important evidence gaps for exosomes.

Hyaluronic acid and corticosteroids

Hyaluronic acid (HA) is an established injectable for knee osteoarthritis. Meta-analyses and a 2025 systematic review have reported greater improvement in pain and function scores with PRP than with HA. Evidence on combining the two is mixed.

Corticosteroids act quickly through anti-inflammatory mechanisms. In lateral elbow epicondylitis, studies have reported better short-term outcomes with corticosteroid injection and better outcomes with PRP at longer follow-up.

Regulatory position

Exosome and stem cell therapies are not FDA-approved for therapeutic use. PRP is classed as a blood product, and PRP applications are considered off-label. Any comparison of these options should weigh evidence, safety, access and regulatory status together.

Educational content for healthcare professionals. Not a treatment recommendation. PRP applications are considered off-label.

Platelet-rich plasma (PRP): 0 of 25 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • Choosing between biologics for a given case
  • Combination approaches and their evidence
  • Cost, access and practical setup
  • Regulatory compliance for each modality
  • Discussing options with patients

Common questions.

Is PRP better than hyaluronic acid for knee osteoarthritis?
Several meta-analyses and a 2025 systematic review have reported greater improvement in pain and function scores with PRP than with HA. PRP use for this purpose is considered off-label.
How is PRP different from exosomes?
PRP contains whole platelets and a broad mix of growth factors from the patient's own blood. Exosomes are vesicles carrying specific molecular signals, often isolated from cultured cells, and are not FDA-approved for therapeutic use.
Are stem cell therapies FDA-approved?
Stem cell therapies are not FDA-approved for therapeutic use. They also face greater regulatory oversight and more complex preparation than PRP.

Sources

  • BMC Musculoskeletal Disorders. "Comparison of hyaluronic acid and platelet-rich plasma in knee osteoarthritis: a systematic review." 2025. https://doi.org/10.1186/s12891-025-08474-6
  • BMC Musculoskeletal Disorders. "Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis." 2025. https://doi.org/10.1186/s12891-025-08566-3
  • Journal of Orthopaedic Surgery and Research. "Adipose-derived mesenchymal stem cells combined with platelet-rich plasma are superior options for the treatment of osteoarthritis." 2024. https://doi.org/10.1186/s13018-024-05396-2

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.